Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market within a 30-day timeframe [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's future earnings and financial health [4] - Momentum Score capitalizes on existing price trends and earnings outlooks [5] - VGM Score combines all three styles to highlight stocks with the best overall potential [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to identify stocks, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock Highlight: TG Therapeutics (TGTX) - TG Therapeutics is focused on developing therapies for B-cell diseases and currently holds a Zacks Rank of 3 (Hold) with a VGM Score of B [12] - The company is projected to experience substantial growth, with an expected year-over-year earnings growth of 893.3% for the current fiscal year [12] - Recent analyst revisions have increased the earnings estimate for fiscal 2025, with the Zacks Consensus Estimate rising to $1.49 per share [13] - TGTX has demonstrated a strong average earnings surprise of +217.5%, making it a noteworthy consideration for growth investors [13]